» Articles » PMID: 20450868

Preclinical Evaluation of the Synthetic Adjuvant SQS-21 and Its Constituent Isomeric Saponins

Overview
Journal Vaccine
Date 2010 May 11
PMID 20450868
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The saponin fraction QS-21 from Quillaja saponaria has been demonstrated to be a potent immunological adjuvant when mixed with keyhole limpet hemocyanin conjugate vaccines, as well as with other classes of subunit antigen vaccines. QS-21 adjuvant is composed of two isomers that include the apiose and xylose forms in a ratio of 65:35, respectively. The chemical syntheses of these two isomers in pure form have recently been disclosed. Herein we describe detailed in vivo immunological evaluations of these synthetic QS-21 isomeric constituents, employing the GD3-KLH melanoma antigen. With this vaccine construct, high antibody titers against GD3 ganglioside and KLH were elicited when GD3-KLH was co-administered with adjuvant, either as the individual separate synthetic QS-21 isomers (SQS-21-Api or SQS-21-Xyl), or as its reconstituted 65:35 isomeric mixture (SQS-21). These antibody titer levels were comparable to that elicited by vaccinations employing naturally derived QS-21 (PQS-21). Moreover, toxicities of the synthetic saponin adjuvants were also found to be comparable to that of naturally derived PQS-21. These findings demonstrate unequivocally that the adjuvant activity of QS-21 resides in these two principal isomeric forms, and not in trace contaminants within the natural extracts. This lays the foundation for future exploration of structure-function correlations to enable the discovery of novel saponins with increased potency, enhanced stability, and attenuated toxicity.

Citing Articles

Design and Synthesis of Immunoadjuvant QS-21 Analogs and Their Biological Evaluation.

Yuan W, Wang Z, Zou Y, Zheng G Biomedicines. 2024; 12(2).

PMID: 38398070 PMC: 10887094. DOI: 10.3390/biomedicines12020469.


cGAMP/Saponin Adjuvant Combination Improves Protective Response to Influenza Vaccination by Microneedle Patch in an Aged Mouse Model.

Vassilieva E, Li S, Korniychuk H, Taylor D, Wang S, Prausnitz M Front Immunol. 2021; 11:583251.

PMID: 33603732 PMC: 7884748. DOI: 10.3389/fimmu.2020.583251.


Synthesis and Evaluation of QS-7-Based Vaccine Adjuvants.

Wang P, Skalamera D, Sui X, Zhang P, Michalek S ACS Infect Dis. 2019; 5(6):974-981.

PMID: 30920199 PMC: 6848976. DOI: 10.1021/acsinfecdis.9b00039.


Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis.

Fernandez-Tejada A, Tan D, Gin D Acc Chem Res. 2016; 49(9):1741-56.

PMID: 27568877 PMC: 5032057. DOI: 10.1021/acs.accounts.6b00242.


Saponin Variants with Central Glycosidic Linkage Modifications Exhibit Distinct Conformations and Adjuvant Activities.

Walkowicz W, Fernandez-Tejada A, George C, Corzana F, Jimenez-Barbero J, Ragupathi G Chem Sci. 2016; 7(3):2371-2380.

PMID: 27014435 PMC: 4800320. DOI: 10.1039/C5SC02978C.


References
1.
Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston P . Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer. 2000; 85(5):659-66. DOI: 10.1002/(sici)1097-0215(20000301)85:5<659::aid-ijc11>3.0.co;2-5. View

2.
Kashala O, Amador R, Valero M, Moreno A, Barbosa A, Nickel B . Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine. 2002; 20(17-18):2263-77. DOI: 10.1016/s0264-410x(02)00115-9. View

3.
Evans T, McElrath M, Matthews T, Montefiori D, Weinhold K, Wolff M . QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine. 2001; 19(15-16):2080-91. DOI: 10.1016/s0264-410x(00)00415-1. View

4.
Zhang S, Cordon-Cardo C, Zhang H, Reuter V, Adluri S, Hamilton W . Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer. 1997; 73(1):42-9. DOI: 10.1002/(sici)1097-0215(19970926)73:1<42::aid-ijc8>3.0.co;2-1. View

5.
Zhang S, Zhang H, Cordon-Cardo C, Ragupathi G, Livingston P . Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens. Clin Cancer Res. 1998; 4(11):2669-76. View